Status:
TERMINATED
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
Lead Sponsor:
Kentuckiana Cancer Institute
Conditions:
Non-small Cell Lung Cancer
Extensive Stage Unresectable
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the do...
Detailed Description
A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Eligibility Criteria
Inclusion
- 18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky PS greater than or equal to 60%
Exclusion
- untreated CNS metastases
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00264134
Start Date
June 1 2003
End Date
October 1 2005
Last Update
January 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202